Table 2. Cox Regression Analysis of Differentially Expressed Proteins for Overall Survival.
| Variable | Univariate | Multivariatea | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (per 10-year increment) | 1.35 (0.91–2.02) | 0.140 | - | - |
| Staging (ENSAT)b | 11.82 (2.49–56.09) | 0.002 | - | - |
| High cyclin B1 | 11.40 (2.47–52.59) | 0.002 | 6.13 (1.02–36.65) | 0.047 |
| High TfR1 | 8.76 (1.94–39.54) | 0.005 | 6.59 (1.14–38.23) | 0.036 |
| High fibronectin | 8.71 (1.93–39.35) | 0.005 | 3.92 (0.75–20.43) | 0.105 |
| High cyclin B1+high TfR1c | 22.23 (4.59–107.61) | <0.001 | 13.72 (1.89–99.66) | 0.010 |
| High cyclin B1+high fibronectinc | 19.44 (4.22–89.57) | <0.001 | 9.22 (1.34–63.55) | 0.024 |
| High TfR1+high fibronectinc | 21.48 (4.57–100.95) | <0.001 | 18.59 (2.54–135.88) | 0.004 |
| High cyclin B1+high TfR1+high fibronectinc | 15.43 (4.05-58.83) | <0.001 | 8.41 (1.54-45.90) | 0.014 |
HR, hazard ratio; CI, confidence interval; ENSAT, European Network for the Study of Adrenal Tumors; TfR1, transferrin receptor.
aMultivariate analyses are adjusted by age and staging; bThe categorization of I+II vs. III+IV was applied using the ENSAT system; cThe reference group is other subjects, such as those except patients with both high cyclin B1 and high TfR1.